

Advanced Diagnostic and Treatment Updates for Canine and Feline Lymphoma
Live Virtual Course | November 9, 2026

Sponsored by



AGENDA Monday, November 9, 2026		
Time (Mountain Time)	Topic	Presenter(s)
8:00 – 8:15 am	Welcome and Introductions	<i>Dr. Margaret Musser</i>
8:15 – 9:15 am	LSA past and present - Upon completion, participants will have a historical timeline for the major updates in diagnosis and treatment in canine and feline lymphoma. - Upon completion, participants will be able to articulate the major molecular drivers of canine and feline oncogenesis and how they differ between animals and humans.	<i>Dr. Douglas Thamm</i>
9:15 – 10:15 am	Flow and any new data on the typical - Be able to identify the range of canine lymphoid malignancies by their primary flow cytometric features. - Identify the clinical situations where flow cytometry is less useful than other methods of diagnosis. - Gain a greater understanding of how flow cytometry has aided in the identification of new disease categories, focusing on small cell B cell lymphoma and acute B cell leukemia.	<i>Dr. Anne Avery</i>
10:15 – 10:30 am	Break	
10:30 – 11:00 am	LSA Panel - Describe the elements of the WHO classification system algorithm. - Explain and differentiate the diagnostic tools used in the pathologic assessment of lymphoma. - Summarize the key pathologic features and outcomes of select common lymphoma subtypes.	<i>Dr. Amy Durham</i>
11:00 – 12:00 pm	Panel Discussion - Review the historical evolution of canine and feline lymphoma diagnosis and treatment, including major milestones in classification systems, immunophenotyping, molecular diagnostics, and therapeutic advances - Differentiate the major canine and feline lymphoid malignancies using contemporary diagnostic modalities - Describe the key molecular and immunophenotypic drivers of canine and feline lymphoma and leukemia	<i>Dr. Douglas Thamm</i> <i>Dr. Anne Avery</i> <i>Dr. Amy Durham</i> <i>Moderator: Dr. Margaret Musser</i>

Advanced Diagnostic and Treatment Updates for Canine and Feline Lymphoma
Live Virtual Course | November 9, 2026

Sponsored by



AGENDA (cont.) Monday, November 9, 2026		
Time (Mountain Time)	Topic	Presenter(s)
12:00 – 1:00 pm	Lunch Break	
1:00 – 2:00 pm	Immunotherapy: Zoetis Monoclonal - Understand the historical context of anti-CD20 monoclonal antibody (mAb) therapy in dogs, and in people. - Map the development of a fully canine anti-CD20 mAb. - Interpret pharmacokinetic/pharmacodynamic and tolerability results from healthy dogs. - Critically evaluate proof-of-concept data in canine B-cell lymphoma—including PK/PD in the disease setting, tolerability, and preliminary efficacy.	<i>Dr. Andi Flory</i>
2:00 – 3:00 pm	Half Body Radiation Therapy for the Treatment of Lymphoma - Understand the rationale for using wide field irradiation in the treatment of canine lymphoma. - Identify current knowledge gaps regarding case selection, dosing, and delivery techniques. - Determine prognosis and prognostic factors for dogs treated with this therapy. - Discuss toxicity and its management.	<i>Dr. Michael Kent</i>
3:00 – 3:15 pm	Break	
3:15 – 4:15 pm	Role of Bone Marrow - Understand how apheresis machines work and their utility in the bone marrow transplant (BMT) setting. - Understand the difference between autologous and allogeneic hematopoietic cell BMTs. - Understand how BMTs can be used to treat and/or cure dogs with lymphoid malignancies and become familiar with the current outcome data we have generated.	<i>Dr. Steve Suter</i>
4:15 – 5:15 pm	Chemosensitivity (Imprimed)	<i>Dr. Kevin Choy</i>
5:15 pm	Closing Remarks	<i>Dr. Margaret Musser</i>